Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
1.560
+0.010 (0.65%)
At close: Jul 25, 2025, 4:00 PM
1.531
-0.029 (-1.87%)
Pre-market: Jul 28, 2025, 8:38 AM EDT
Repare Therapeutics Employees
Repare Therapeutics had 129 employees as of December 31, 2024. The number of employees decreased by 50 or -27.93% compared to the previous year.
Employees
129
Change (1Y)
-50
Growth (1Y)
-27.93%
Revenue / Employee
$8,318
Profits / Employee
-$991,426
Market Cap
66.91M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 129 | -50 | -27.93% |
| Dec 31, 2023 | 179 | -1 | -0.56% |
| Dec 31, 2022 | 180 | 28 | 18.42% |
| Dec 31, 2021 | 152 | 50 | 49.02% |
| Dec 31, 2020 | 102 | 38 | 59.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RPTX News
- 12 days ago - Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - Business Wire
- 2 months ago - Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results - Business Wire
- 3 months ago - Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - Business Wire
- 3 months ago - Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - Business Wire
- 3 months ago - Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - Business Wire
- 4 months ago - Repare Therapeutics Announces Leadership Transitions - Business Wire
- 5 months ago - Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 months ago - Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire